March 31, 2004

Farmingdale, NY

 

Misonix Launches Prostate Cancer Product at European Urology Association Meeting in Vienna; New Data Show 88% Success Rate in Treating Cancer

 

Misonix, Inc today announced that it has launched the Sonablate 500 in Western Europe, Eastern Europe and Russia, for the treatment of prostate cancer, enlarged prostate and other prostatic tumors. The product launch came in conjunction with the release of new data at the European Urology Association meeting in Vienna, Austria presented by Dr John Rewcastle, a prominent figure in the field of urology. The report, which was sponsored by Misonix, includes data showing that the Sonablate 500 is 88% effective in producing PSA measurements below 1.0 within one year following treatment using the Sonablate 500. The data also showed the product had a favorable safety profile compared to other methods of treatment.

 

The Sonablate 500 uses High Intensity Focused Ultrasound (HIFU) in the non-invasive treatment of prostate cancer, enlarged prostate and other prostatic tumors. The device has a CE mark, has been successful in treating more than 150 patients in Germany to date and has been used in clinical applications throughout Europe.

 

Dr. Joachin Deuster, MD from the Prostata Therapie Tageslink fur Urologie in Heidelberg, Germany stated, “Over the past 2 years with the help of the Sonablate 500, I have treated over 180 prostate cancer patients using the Sonoblate without any major complications. This system preserves the quality of life. Patients do not suffer the same level of incontinency and impotency using the Sonoblate 500 in comparison to other treatment methods. I believe that the HIFU is the treatment method of the future for prostate cancer. The system is simple and is used on an outpatient basis”.